Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors

Source: PRNewswire· July 27, 2026

Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway Global Phase 1 multicenter study evaluates safety, tolerability, and preliminary efficacy in patients with mesothelioma and other a…

This story was reported by PRNewswire. Read the full original article:

Read on PRNewswire

More in Ethics & Safety

View all

Defending the Future, Today: Cisco Resilient Infrastructure Services

Learn how Cisco Resilient Infrastructure Services deliver solutions to manage machine-speed risk and exposure management now.

Cisco.com · Jul 27, 2026

Willis urges smarter data center insurance buying as capacity demand nears US $15 billion

Client insights show that sharper risk quantification can help stakeholders across the digital infrastructure ecosystem avoid unnecessary insurance spend while strengthening operational resilience Client insights show that sharper risk quantification can help…

GlobeNewswire · Jul 27, 2026

The Next Evolution of OT Cybersecurity Isn't Finding Risk - It's Reducing It.

TXOne Networks redefines success in OT cybersecurity by transforming cyber visibility into continuous operational cyber risk reduction. IRVING, Texas, July 27, 2026 /PRNewswire/ -- Industrial organizations have made tremendous progress in cyber visibility. As…

PRNewswire · Jul 27, 2026

Revolut to give Irish users access to private market investment funds

Fintech is working with Apollo, Ares and others to allow retail investors tap into new markets suitable for long-term investors with appetite for risk

The Irish Times · Jul 27, 2026